Open access
Open access
Powered by Google Translator Translator

Hematology (all articles)

Dose-reduced direct oral anticoagulants: practical considerations.

31 Oct, 2022 | 13:52h | UTC

Peripheral Matters | Dose-Reduced Direct Oral Anticoagulants: Practical Considerations – American College of Cardiology

 

Post-trial follow-up | Updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.

31 Oct, 2022 | 13:36h | UTC

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab – Blood

 

Commentary on Twitter

 

RCT | Sutimlimab in patients with cold agglutinin disease without recent transfusion.

31 Oct, 2022 | 13:37h | UTC

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial – Blood

Editorial: A virtuosic CADENZA played by sutimlimab – Blood

Commentary: Sutimlimab Shows Efficacy in Patients With CAD Without Recent Transfusion – AJMC

 

Commentary on Twitter

 

Case Report | Acquired Hemophilia A secondary to an immune checkpoint inhibitor.

31 Oct, 2022 | 13:34h | UTC

Acquired Hemophilia A Secondary to an Immune Checkpoint Inhibitor: A Case Report – JTO Clinical and Research Reports

Commentary: Report Details Rare Case of Acquired Hemophilia A Secondary to Immune Checkpoint Inhibition

 

Review | Iron deficiency and cardiovascular disease.

27 Oct, 2022 | 12:31h | UTC

Iron deficiency and cardiovascular disease – European Heart Journal

 

Commentary on Twitter

Under a https://creativecommons.org/licenses/by-nc/4.0/ license

 

Recommendations for laboratory testing of patients with acute myeloid leukemia.

25 Oct, 2022 | 13:21h | UTC

A British Society for Haematology good practice paper: Recommendations for laboratory testing of UK patients with acute myeloid leukaemia – British Journal of Haematology

 

Systematic Review | Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.

21 Oct, 2022 | 12:47h | UTC

Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines – Cochrane Library

Summary: Can the medicine dexrazoxane prevent or reduce heart damage in adults and children with cancer receiving anthracyclines? – Cochrane Library

 

Guideline | Diagnosis and management of febrile neutropenia in patients with cancer.

18 Oct, 2022 | 12:52h | UTC

The Dutch Working Party on Antibiotic Policy (SWAB) Recommendations for the Diagnosis and Management of Febrile Neutropenia in Patients with Cancer – Infectious Diseases and Therapy

Related:

Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update – Journal of Clinical Oncology

Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO) – Annals of Hematology

SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018) – Clinical and Translational Oncology

Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)

Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update

 

Guidance | Peri-procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology.

13 Oct, 2022 | 13:46h | UTC

Peri-procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology: Guidance from the SSC of the ISTH – Journal of Thrombosis & Haemostasis

 

Cohort Study | Cardiovascular morbidity in monoclonal gammopathy of undetermined significance.

13 Oct, 2022 | 13:34h | UTC

Cardiovascular Morbidity in Monoclonal Gammopathy of Undetermined Significance: A Danish Nationwide Study – JACC: CardioOncology

Editorial: Cardiovascular Associations With Monoclonal Gammopathy of Undetermined Significance: Real or Coincidental? – JACC: CardioOncology

 

Guideline | Evaluation and management of venous thromboembolism.

12 Oct, 2022 | 13:55h | UTC

Joint Guideline on Venous Thromboembolism – 2022 – Arquivos Brasileiros de Cardiologia

 

Review | Point of care coagulation management in anesthesiology and critical care.

7 Oct, 2022 | 14:06h | UTC

Point of care coagulation management in anesthesiology and critical care – Minerva Anestesiologica

 

Phase 1 study | GPRC5D-Targeted CAR T Cells for patients with heavily pretreated Multiple Myeloma.

29 Sep, 2022 | 13:25h | UTC

GPRC5D-Targeted CAR T Cells for Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)

 

Review | Direct-acting oral anticoagulant prescriptions in the emergency department.

27 Sep, 2022 | 13:08h | UTC

Direct-Acting Oral Anticoagulant Prescriptions in the ED – emDocs

 

Platelet dysfunction after trauma: from mechanisms to targeted treatment.

26 Sep, 2022 | 11:56h | UTC

Platelet dysfunction after trauma: From mechanisms to targeted treatment – Transfusion

 

Effects of tranexamic acid treatment in severely and non-severely injured trauma patients.

26 Sep, 2022 | 11:54h | UTC

Effects of tranexamic acid treatment in severely and non-severely injured trauma patients – Transfusion

 

Guideline | Anemia management in surgical patients.

23 Sep, 2022 | 13:11h | UTC

Recommendations from the International Consensus Conference on Anemia Management in Surgical Patients (ICCAMS) – Annals of Surgery

 

Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations.

23 Sep, 2022 | 13:07h | UTC

Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations – The BMJ

 

Commentary on Twitter

 

A quality improvement study showed that a clinic–based aspirin deimplementation intervention can reduce inappropriate aspirin prescribing and bleeding in patients receiving warfarin for anticoagulation.

22 Sep, 2022 | 13:14h | UTC

Assessment of an Intervention to Reduce Aspirin Prescribing for Patients Receiving Warfarin for Anticoagulation – JAMA Network Open

News Release: Stopping aspirin when on a blood thinner lowers risk of bleeding, study finds – Michigan Medicine

 

Commentary on Twitter

 

Case report and brief review | Severe thrombotic complications secondary to antiphospholipid syndrome and undiagnosed systemic lupus erythematosus.

20 Sep, 2022 | 13:17h | UTC

Severe thrombotic complications secondary to antiphospholipid syndrome and undiagnosed systemic lupus erythematosus – Canadian Medical Association Journal

 

AHA Scientific Statement | Management of patients at risk for and with left ventricular thrombus.

16 Sep, 2022 | 13:00h | UTC

Management of Patients at Risk for and With Left Ventricular Thrombus: A Scientific Statement From the American Heart Association – Circulation

 

Review | Obesity and contraceptive use: impact on cardiovascular risk.

16 Sep, 2022 | 12:53h | UTC

Obesity and contraceptive use: impact on cardiovascular risk – ESC Heart Failure

News Release: Combined birth control pill linked with increased risk of blood clots in obese women – European Society of Cardiology

 

NCCN Guideline | Myeloproliferative neoplasms.

15 Sep, 2022 | 13:05h | UTC

Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology – National Comprehensive Cancer Network

 

M-A | Blood type linked to the risk of stroke before age 60.

13 Sep, 2022 | 13:17h | UTC

Contribution of Common Genetic Variants to Risk of Early Onset Ischemic Stroke – Neurology (link to abstract – $ for full-text)

News Releases:

Is your blood type linked to your risk of stroke before age 60? – American Academy of Neurology

Blood Type Linked To Stroke Risk Before 60 – University of Maryland

 

Retrospective cohort study | Tisagenlecleucel (an anti-CD19 CAR T-cell therapy) for relapsed or refractory B-cell acute lymphoblastic leukemia in infants and children younger than 3 years of age at screening.

13 Sep, 2022 | 12:59h | UTC

Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study – The Lancet Haematology

Commentaries:

CD19 CAR T cells for infants and young children – The Lancet Haematology (free registration required)

CAR-T Therapy Effective in Youngest Kids With ALL — Analysis shows safety and outcomes equivalent to those reported in older children – MedPage Today (free registration required)

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.